Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | S1PR5 | Q9H228 | 8/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17963504 | 0.88 | KDM4E (0.65) | KDM4EKDM1A | |
| SCHEMBL28175300 | 0.86 | KDM4E (0.50) | KDM4EHRH3KDM1ADRD2DRD4 | |
| SCHEMBL15033023 | 0.86 | KDM4E (0.50) | KDM4EHRH3KDM1ADRD2DRD4 | |
| SCHEMBL12814152 | 0.85 | KDM1A (0.53) | KDM4EHRH3KDM1ADRD2DRD4 | |
| SCHEMBL20843153 | 0.85 | KDM1A (0.53) | KDM4EKDM1ADRD2DRD4SIRT2 | |
| SCHEMBL20843229 | 0.84 | KDM1A (0.52) | KDM4EKDM1ADRD2DRD4SIRT2 | |
| SCHEMBL21088709 | 0.84 | CXCR3 (0.53) | KDM4EKDM1ADRD4SIRT2SIRT1 | |
| SCHEMBL17987974 | 0.84 | KDM1A (0.52) | KDM4EKDM1ADRD2DRD4 | |
| SCHEMBL12813914 | 0.84 | KDM4E (0.48) | KDM4EKDM1ADRD2DRD4SIRT2 | |
| SCHEMBL3689873 | 0.82 | HRH3 (0.55) | KDM4EHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107438593-B | Therapeutic compounds and uses thereof | 基因泰克公司 | 2020-10-30 | — | — | CN | disclosed |
| US-10301253-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| EP-3250552-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2019-03-27 | — | — | EP | disclosed |
| US-20180009735-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| EP-3250552-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| WO-2016123387-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016123387-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009735-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM1B, HDAC1, DOT1L | KDM4E 38/4885S1PR5 847/4885HRH3 589/4885 |
| US-10301253-B2 | Therapeutic compounds and uses thereof | KDM1B, HDAC1, DOT1L | KDM4E 38/4885S1PR5 847/4885HRH3 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.